trabedersen

Trabedersen is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) that specifically targets the mRNA encoding transforming growth factor beta2 (TGF-beta2). By binding to TGF-beta2 mRNA, trabedersen inhibits its translation and reduces intratumoral levels of TGF-beta2 protein. This leads to decreased tumor cell growth, migration, and angiogenesis. Trabedersen is being investigated primarily for high-grade glioma (including glioblastoma), pancreatic cancer, malignant melanoma, colorectal cancer, and non-small cell lung cancer. It has orphan drug status for malignant melanoma, pancreatic cancer, and glioma. The drug was originally developed by Antisense Pharma and has been further developed by companies including Autotelic Therapeutics/Oncotelic Therapeutics[1][3][5][7][8].

Brand names

Oncomun

Other names

DNA, D(P-thio)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)Personalised dosing TGF-beta antisenseTGF-beta antisense